Tissue and Plasma Biomarkers of Lymph Node Involvement in Cervical Cancer
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Tissue and Plasma Biomarkers of Lymph Node Involvement in Cervical Cancer|
- Biomarkers (genes and proteins) of lymph node involvement [ Time Frame: 4 years ]
Biospecimen Retention: Samples With DNA
|Study Start Date:||February 2012|
|Estimated Study Completion Date:||January 1, 2019|
|Estimated Primary Completion Date:||January 1, 2019 (Final data collection date for primary outcome measure)|
Other: Blood draw
Other: Blood draw
SPECIFIC STUDY AIMS
Specific Aim 1: To use gene expression analysis of primary cervical cancers to identify a gene expression signature that predicts for lymph node metastases in this disease.
Specific Aim 2: To predict lymph node metastases by performing multiplex measurements of cancer-associated proteins and cytokines using proximity ligation assay (PLA) on plasma samples.
Specific Aim 3: To measure circulating human papilloma virus (HPV) DNA in the plasma samples of cervical cancer patients using real-time quantitative polymerase chain reaction (qPCR) and determine its ability to predict for nodal metastases.
Specific Aim 4: To use deep sequencing to evaluate gene and sequence differences between cervical cancer patients with and without lymph node metastasis.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01546363
|Contact: Dylann Fujimotoemail@example.com|
|United States, California|
|Stanford University, School of Medicine||Recruiting|
|Stanford, California, United States, 94305|
|Contact: Dylann Fujimoto 650-723-8843 firstname.lastname@example.org|
|Sub-Investigator: Albert Koong, MD|
|Principal Investigator:||Elizabeth Kidd, MD||Stanford University|